NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.
Other research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, August 25th. UBS Group reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. BTIG Research boosted their price objective on shares of NRx Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Tuesday, November 3rd. Finally, Wolfe Research assumed coverage on shares of NRx Pharmaceuticals in a research report on Thursday, October 15th. They set an “outperform” rating on the stock. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, NRx Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $35.00.
View Our Latest Analysis on NRx Pharmaceuticals
NRx Pharmaceuticals Stock Performance
NRXP opened at $2.15 on Friday. The stock has a market capitalization of $93.85 million, a price-to-earnings ratio of -6.32 and a beta of 2.11. The company has a fifty day moving average of $2.72 and a 200 day moving average of $2.97. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05.
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.16. The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.28 million. On average, equities research analysts forecast that NRx Pharmaceuticals will post -1.14 earnings per share for the current year.
Institutional Investors Weigh In On NRx Pharmaceuticals
Several hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals in the 2nd quarter valued at about $54,000. SBI Securities Co. Ltd. boosted its holdings in shares of NRx Pharmaceuticals by 292.1% during the 3rd quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company’s stock worth $58,000 after purchasing an additional 14,900 shares during the last quarter. Prime Capital Investment Advisors LLC purchased a new stake in shares of NRx Pharmaceuticals in the third quarter valued at approximately $364,000. Commonwealth Equity Services LLC increased its stake in shares of NRx Pharmaceuticals by 30.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock worth $1,725,000 after acquiring an additional 136,350 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in NRx Pharmaceuticals by 411.4% during the third quarter. Marshall Wace LLP now owns 995,172 shares of the company’s stock worth $2,906,000 after purchasing an additional 800,592 shares during the period. 4.27% of the stock is owned by hedge funds and other institutional investors.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.
Further Reading
- Five stocks we like better than NRx Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
